Literature DB >> 9066328

Identification of heterozygous and homozygous individuals with the novel RYR1 mutation Cys35Arg in a large kindred.

P J Lynch1, R Krivosic-Horber, H Reyford, N Monnier, K Quane, P Adnet, G Haudecoeur, I Krivosic, T McCarthy, J Lunardi.   

Abstract

BACKGROUND: Malignant hyperthermia (MH) is a potentially fatal, often autosomal dominant, disorder of skeletal muscle and is triggered in susceptible people by all commonly used inhalational anesthetics. In this article, the authors describe a malignant hyperthermia susceptible (MHS) kindred in which both parents of the proband are MHS and are first-degree cousins. Haplotype analysis in this kindred with chromosome 19 linked markers revealed that the proband and another sibling were homozygous for the affected RYR1 allele.
METHODS: Eighteen members of this large pedigree were investigated, with a clinical examination for signs of a myopathy, a caffeine halothane contracture test, a histo-enzymologic study on the muscle biopsies, and linkage analysis on genomic DNA isolated from family blood samples. RYR1 cDNA was amplified by polymerase chain reaction and was cloned and sequenced, facilitating mutation detection.
RESULTS: Linkage analysis demonstrated linkage between RYR1-linked markers and MH susceptibility in this family. DNA sequencing identified a T to C transition at nucleotide position 103, resulting in the substitution of an arginine for cysteine 35, representing the most N-terminal mutation reported to date in the RYR1 gene. This mutation segregates fully with the MHS trait, generating a lod score of 4.65 in favor of linkage to MHS at a recombination frequency of 0.0.
CONCLUSIONS: The proband in this kindred is the first reported homozygote to have presented with an MH episode. The homozygotes in this pedigree do not have an overt myopathy. The sensitivity of muscle samples to caffeine clearly distinguished the two homozygotes from other heterozygous-susceptible individuals. No clear differentiation was observed with the halothane contracture results.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9066328     DOI: 10.1097/00000542-199703000-00014

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  12 in total

Review 1.  To fire the train: a second malignant-hyperthermia gene.

Authors:  K Hogan
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

2.  Gene dose influences cellular and calcium channel dysregulation in heterozygous and homozygous T4826I-RYR1 malignant hyperthermia-susceptible muscle.

Authors:  Genaro C Barrientos; Wei Feng; Kim Truong; Klaus I Matthaei; Tianzhong Yang; Paul D Allen; José R Lopez; Isaac N Pessah
Journal:  J Biol Chem       Date:  2011-12-02       Impact factor: 5.157

3.  Mice expressing T4826I-RYR1 are viable but exhibit sex- and genotype-dependent susceptibility to malignant hyperthermia and muscle damage.

Authors:  Benjamin Yuen; Simona Boncompagni; Wei Feng; Tianzhong Yang; Jose R Lopez; Klaus I Matthaei; Samuel R Goth; Feliciano Protasi; Clara Franzini-Armstrong; Paul D Allen; Isaac N Pessah
Journal:  FASEB J       Date:  2011-11-30       Impact factor: 5.191

4.  Mutation screening of the RYR1 gene and identification of two novel mutations in Italian malignant hyperthermia families.

Authors:  V Barone; O Massa; E Intravaia; A Bracco; A Di Martino; V Tegazzin; S Cozzolino; V Sorrentino
Journal:  J Med Genet       Date:  1999-02       Impact factor: 6.318

5.  Oxygen-coupled redox regulation of the skeletal muscle ryanodine receptor/Ca2+ release channel (RyR1): sites and nature of oxidative modification.

Authors:  Qi-An Sun; Benlian Wang; Masaru Miyagi; Douglas T Hess; Jonathan S Stamler
Journal:  J Biol Chem       Date:  2013-06-24       Impact factor: 5.157

6.  Identification of novel mutations in the ryanodine-receptor gene (RYR1) in malignant hyperthermia: genotype-phenotype correlation.

Authors:  B M Manning; K A Quane; H Ording; A Urwyler; V Tegazzin; M Lehane; J O'Halloran; E Hartung; L M Giblin; P J Lynch; P Vaughan; K Censier; D Bendixen; G Comi; L Heytens; K Monsieurs; T Fagerlund; W Wolz; J J Heffron; C R Muller; T V McCarthy
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

7.  Intracellular calcium homeostasis in human primary muscle cells from malignant hyperthermia-susceptible and normal individuals. Effect Of overexpression of recombinant wild-type and Arg163Cys mutated ryanodine receptors.

Authors:  K Censier; A Urwyler; F Zorzato; S Treves
Journal:  J Clin Invest       Date:  1998-03-15       Impact factor: 14.808

Review 8.  Malignant Hyperthermia in the Post-Genomics Era: New Perspectives on an Old Concept.

Authors:  Sheila Riazi; Natalia Kraeva; Philip M Hopkins
Journal:  Anesthesiology       Date:  2018-01       Impact factor: 7.892

9.  Screening for mutations in the RYR1 gene in families with malignant hyperthermia.

Authors:  Viviane P Muniz; Helga C A Silva; Ana Maria C Tsanaclis; Mariz Vainzof
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 3.444

10.  A double mutation of the ryanodine receptor type 1 gene in a malignant hyperthermia family with multiminicore myopathy.

Authors:  Seul-Ki Jeong; Dong-Chan Kim; Yong-Gon Cho; Il-Nam Sunwoo; Dal-Sik Kim
Journal:  J Clin Neurol       Date:  2008-09-30       Impact factor: 3.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.